Actively Recruiting
Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development
Led by Instituto de Investigación Sanitaria Aragón · Updated on 2026-05-12
34
Participants Needed
1
Research Sites
354 weeks
Total Duration
On this page
Sponsors
I
Instituto de Investigación Sanitaria Aragón
Lead Sponsor
C
Cooperativas Lacteas Unidas
Collaborating Sponsor
AI-Summary
What this Trial Is About
Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy
CONDITIONS
Official Title
Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with high-risk colorectal polyps or related conditions including: at least 10 adenomas, at least 5 proximal serrated polyps, at least 2 serrated polyps ≥10 mm, Serrated Polyposis Syndrome, early invasive colorectal cancer stage pT1 resected endoscopically, sessile or flat lesion ≥20 mm with fragmented resection, previous polyp resection with unassessable margin, or intramucosal carcinoma in situ (pTis)
- Regular consumer of milk and dairy products
- Signed informed consent form
You will not qualify if you...
- History of allergic reaction to compounds similar to the study products
- Incomplete or poor quality colonoscopy (Boston score <6)
- Regular or predictable use of acetylsalicylic acid, NSAIDs, misoprostol, corticosteroids, or statins during the study
- Previous gastrointestinal surgery affecting nutrient absorption
- History of familial adenomatous polyposis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Angel Lanas Arbeloa
Zaragoza, Zaragoza, Spain, 50009
Actively Recruiting
Research Team
A
Angel Lanas Arbeloa, MD, PhD
CONTACT
P
Pilar Irun, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here